Addiction, Author Interviews, JAMA, Opiods / 24.04.2020

MedicalResearch.com Interview with: Tami L. Mark, PhD Senior Director, Behavioral Health Financing and Quality Measurement RTI International  MedicalResearch.com: What is the background for this study? Response: There are effective medications to treat opioid use disorder. Federal and state policymakers have tried to improve access to these medications. However, medications to treat opioid use disorders are still often subject to prior authorization. Studies of other medications finds that prior authorization can reduce access. This study looked at whether removing prior authorization in Medicare Part D plans was associated with increases in the use of medications to treat opioid use disorder.  (more…)
Author Interviews, Lyme / 13.03.2020

MedicalResearch.com Interview with: Donal Bisanzio PhD DVM Senior Epidemiologist RTI International MedicalResearch.com: What is the background for this study? Response: The number of reported cases of Lyme disease has steadily increased since the year 2000. The Centers for Disease Control Prevention (CDC) estimates that nearly 30,000 cases are reported each year with close to 270,000 unreported cases. The high fraction of unreported cases is linked with the absence of specific disease symptoms, which can deter physicians from an initial diagnosis. Another critical factor causing underreporting is the low accuracy of methods used to test Lyme disease. These factors show us that some counties that are currently considered Lyme disease-free may only have this status due to underreporting. RTI International, in collaboration with Columbia University, built a model to show factors affecting the diffusion of case reporting in the north-eastern U.S. from 2000 to 2017 and identify which counties may be experiencing underreporting. The model used publicly available data published each year by the CDC on cases reported at the county-level merged with information on vector distribution and data obtained by satellite surveys. The model included 855 counties located in 31 states in the West North Central, East North Central, New England, Mid-Atlantic, and Southern regions of the U.S. The final product was a map showing the probability of counties of the north-eastern U.S. to report Lyme disease cases.  (more…)
Addiction, Author Interviews, Opiods / 05.10.2018

MedicalResearch.com Interview with: "150826-fentanyl-factory-underground-illicit.jpg" by r. nial bradshaw is licensed under CC BY 2.0 Jon Zibbell, PhD, Senior public health scientist Behavioral Health Research Division RTI International Research Triangle Park, NC,  MedicalResearch.com: What is the background for this study? What are the main findings? Response: For the first time in 2016, U.S. overdose deaths involving illicitly-manufactured fentanyl surpassed deaths from heroin and prescription deaths. Fentanyl is an extremely potent synthetic opioid, and an illicitly-manufactured form of the drug is regularly being mixed with heroin and often sold to unwitting consumers. Fentanyl is 50 times more potent than heroin and its illicitly-manufactured version is extremely difficult to discern when mixed with heroin. Harm reduction organizations have started to distribute FTS and people consuming street-purchased opioids are using them to test drugs for fentanyl. Our objective was to assess whether this point-of-use form of drug checking was influencing people’s drug use behavior. The study was self-funded by the research institute RTI International. Our findings show that consumers who tested street opioids with fentanyl test strips were five times more likely to engage in safer drug use behavior when the test comes back positive. The study was conducted among a group of 125 people who inject drugs in Greensboro, North Carolina. (more…)